Aromatic-Cationic Peptides for Mitochondrial Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods are inadequate in effectively addressing oxidative damage and mitochondrial dysfunction, particularly in reducing mitochondrial permeability transition and enhancing ATP synthesis in mammals.
Innovation Solution
Administration of aromatic-cationic peptides, which localize to mitochondria, reducing oxidative damage and increasing ATP synthesis by mitigating mitochondrial permeability transition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic methods are used, then treatment is provided, but they are inadequate in effectively addressing oxidative damage and mitochondrial dysfunction
Solution Approach 1:
The patent modifies the chemical structure of cationic peptides by incorporating aromatic amino acids (phenylalanine, tyrosine, tryptophan) at specific positions to create aromatic-cationic peptides. This structural parameter change enhances the peptides' ability to localize to mitochondria and protects against oxidative damage, directly resolving the inadequacy of current therapeutic methods for mitochondrial dysfunction
Solution Approach 2:
The invention creates composite peptide structures combining cationic amino acids (arginine, lysine) with aromatic amino acids. This composite structure enables simultaneous electrostatic interaction with mitochondrial membranes and protection against oxidative damage through aromatic side chains, providing both mitochondrial targeting and antioxidant functionality that current single-function therapies lack
2Reliability
If mitochondrial permeability transition is reduced, then cell death is prevented, but current methods cannot effectively achieve this reduction
Solution Approach 1:
The aromatic-cationic peptides are administered before oxidative damage occurs or at the onset of mitochondrial stress. They preemptively localize to mitochondria and prevent permeability transition pore formation, stopping the cascade toward cell death before it begins. This preliminary protective action is more effective than attempting to reverse established damage
3Stability of the object's composition
If oxidative damage is reduced, then tissue integrity is maintained, but current therapies cannot effectively decrease oxidative damage
Solution Approach 1:
The aromatic-cationic peptides contain cationic amino acids that are normally susceptible to oxidative modification. However, the patent utilizes this susceptibility by designing peptides where oxidative modification of the cationic residues actually enhances their mitochondrial localization and protective function. The potential harm of oxidative susceptibility is converted into a benefit for targeted mitochondrial protection
Solution Approach 2:
The aromatic-cationic peptides act as intermediary molecules between the oxidative environment and mitochondrial structures. They absorb oxidative stress through their aromatic and cationic side chains, serving as a buffer that protects mitochondrial membranes and proteins from direct oxidative damage, thereby maintaining tissue integrity
Data Source
AI summary
The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.